The following IPOs are expected to price this week:
Aratana Therapeutics (PETX), which is developing medications for cats and dogs based on therapies for humans, plans to raise $51 million by offering 4.3 million shares at a price range of $11.00 to $13.00. At the midpoint of the proposed range, Aratana Therapeutics would command a market value of $217 million. Aratana Therapeutics was founded in 2010. The Kansas City, KS-based company plans to list on the NASDAQ under the symbol PETX. Stifel and Lazard Capital Markets are the joint bookrunners on the deal.
bluebird bio (BLUE), which is developing gene therapies for severe genetic and orphan diseases, plans to raise $75 million by offering 5.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, bluebird bio would command a market value of $374 million. bluebird bio, which was founded in 1992, booked $1 million in sales over the last 12 months. The Cambridge, MA-based company plans to list on the NASDAQ under the symbol BLUE. J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal.
Gogo (GOGO), the leading provider of in-flight WiFi on commercial and business jets, plans to raise $176 million by offering 11.0 million shares at a price range of $15.00 to $17.00. At the midpoint of the proposed range, Gogo would command a market value of $1.4 billion. Gogo, which was founded in 1991, booked $250 million in sales over the last 12 months. The Itasca, IL-based company plans to list on the NASDAQ under the symbol GOGO. Morgan Stanley, J.P. Morgan and UBS Investment Bank are the joint bookrunners on the deal.
PTC Therapeutics (PTCT), a biotech targeting rare forms of muscular dystrophy and cystic fibrosis, plans to raise $100 million by offering 6.9 million shares at a price range of $13.00 to $16.00. At the midpoint of the proposed range, PTC Therapeutics would command a market value of $322 million. PTC Therapeutics, which was founded in 1998, booked $29 million in sales over the last 12 months. The South Plainfield, NJ-based company plans to list on the NASDAQ under the symbol PTCT. J.P. Morgan and Credit Suisse are the joint bookrunners on the deal.
Regado Biosciences (RGDO), which is developing break-through anticoagulant system for cardiovascular surgeries, plans to raise $75 million by offering 5.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Regado Biosciences would command a market value of $219 million. Regado Biosciences, which was founded in 2001, booked $0 million in sales over the last 12 months. The Basking Ridge, NJ-based company plans to list on the NASDAQ under the symbol RGDO. Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal.
Votorantim Cimentos S.A. (VEBM), Brazil's largest cement producer with 37% market share, plans to raise $3.4 billion by offering 200.0 million shares at a price range of $15.59 to $18.51. At the midpoint of the proposed range, Votorantim Cimentos S.A. would command a market value of $17.9 billion. Votorantim Cimentos S.A., which was founded in 1933, booked $4.9 billion in sales over the last 12 months. The São Paulo, Brazil-based company plans to list on the NYSE under the symbol VEBM. Morgan Stanley, J.P. Morgan, Itau BBA and Credit Suisse are the joint bookrunners on the deal. (Please note: Dual listing on NYSE and São Paulo Stock Exchange.)
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
Last week, there were 2 IPO pricings. Gigamon (GIMO), which provides data traffic management software-based appliances, was the week's winner, ending up 50% from its IPO price.
